| Features: |
| Curcumin is the main active ingredient in Tumeric. Member of the ginger family.Curcumin is a polyphenol extracted from turmeric with anti-inflammatory and antioxidant properties. - Has iron-chelating, iron-chelating properties. Ferritin. But still known to increase Iron in Cancer cells. - GSH depletion in cancer cells, exhaustion of the antioxidant defense system. But still raises GSH↑ in normal cells. - Higher concentrations (5-10 μM) of curcumin induce autophagy and ROS production - Inhibition of TrxR, shifting the enzyme from an antioxidant to a prooxidant - Strong inhibitor of Glo-I, , causes depletion of cellular ATP and GSH - Curcumin has been found to act as an activator of Nrf2, (maybe bad in cancer cells?), hence could be combined with Nrf2 knockdown -may suppress CSC: suppresses self-renewal and pathways (Wnt/Notch/Hedgehog). Clinical studies testing curcumin in cancer patients have used a range of dosages, often between 500 mg and 8 g per day; however, many studies note that doses on the lower end may not achieve sufficient plasma concentrations for a therapeutic anticancer effect in humans. • Formulations designed to improve curcumin absorption (like curcumin combined with piperine, nanoparticle formulations, or liposomal curcumin) are often employed in clinical trials to enhance its bioavailability. -Note half-life 6 hrs. BioAv is poor, use piperine or other enhancers Pathways: - induce ROS production at high concentration. Lowers ROS at lower concentrations - ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓ - Lowers AntiOxidant defense in Cancer Cells: GSH↓ Catalase↓ HO1↓ GPx↓ but conversely is known as a NRF2↑ activator in cancer - Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑, - lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : TNF-α↓, IL-6↓, IL-8↓ - inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, uPA↓, VEGF↓, NF-κB↓, CXCR4↓, SDF1↓, TGF-β↓, α-SMA↓, ERK↓ - reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMT1↓, DNMT3A↓, EZH2↓, P53↑, HSP↓, Sp proteins↓, - cause Cell cycle arrest : TumCCA↑, cyclin D1↓, CDK2↓, CDK4↓, CDK6↓, - inhibits Migration/Invasion : TumCMig↓, TumCI↓, ERK↓, EMT↓, TOP1↓, TET1↓, - inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDHA↓, HK2↓, PFKs↓, PDKs↓, HK2↓, ECAR↓, OXPHOS↓, GRP78↑, GlucoseCon↓ - inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓, - inhibits Cancer Stem Cells : CSC↓, CK2↓, Hh↓, GLi1↓, CD133↓, CD24↓, β-catenin↓, n-myc↓, sox2↓, OCT4↓, - Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK↓, ERK↓, JNK, TrxR**, - Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective, - Selectivity: Cancer Cells vs Normal Cells |
| Source: |
| Type: |
| Cancer Stem Cells Phytochemicals (natural plant-derived compounds) that may affect CSCs: Curcumin — suppresses self-renewal and pathways (Wnt/Notch/Hedgehog). Resveratrol — shown to reduce CSC populations and sphere formation in multiple models. Sulforaphane (from broccoli sprouts) — reported to inhibit CSC properties and pathways; active in vitro and in vivo. EGCG (epigallocatechin-3-gallate, green tea) — reduces CSC markers and sphere formation in several cancer types. Quercetin — reported to inhibit CSC proliferation, self-renewal and invasiveness (breast, endometrial, others). Berberine — shown to suppress CSC “stemness” and reduce tumorigenic properties in multiple models. Genistein (soy isoflavone) — decreases CSC markers, sphere formation and stemness signaling in prostate/breast/other models. Honokiol (Magnolia bark) — shown to eliminate or suppress CSC-like populations in oral, colon, glioma models. Luteolin — inhibits stemness/EMT and reduces CSC markers and self-renewal in breast, prostate and other models. Withaferin A (from Withania somnifera / ashwagandha) — multiple preclinical reports show WA targets CSCs and reduces tumor growth/metastasis in models. |
| 4656- | CUR, | EGCG, | Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 |
| 2688- | CUR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4655- | CUR, | Inhibition of Cancer Stem-like Cells by Curcumin and Other Polyphenol Derivatives in MDA-MB-231 TNBC Cells |
| - | in-vitro, | BC, | NA |
| 4653- | CUR, | Curcumin: a promising agent targeting cancer stem cells |
| - | Review, | Var, | NA |
| 4652- | CUR, | Anticancer effect of curcumin on breast cancer and stem cells |
| - | Review, | BC, | NA |
| 4651- | CUR, | Targeting cancer stem cells by curcumin and clinical applications |
| - | Review, | Var, | NA |
| 450- | CUR, | Curcumin may be a potential adjuvant treatment drug for colon cancer by targeting CD44 |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HCT8 |
| 437- | CUR, | Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids |
| - | vitro+vivo, | CRC, | TCO1 | - | vitro+vivo, | CRC, | TCO2 |
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:65 Target#:795 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid